Show results for
Refine by
Disease Modeling Suppliers Serving Swaziland
60 companies found
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
based inNeedham, MASSACHUSETTS (USA)
Invicro is an integral part of the REALM IDx, Inc. group, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. As a global research partner to the ...
based inLancaster, CALIFORNIA (USA)
Simulations Plus provides cutting-edge software solutions and consulting services designed to enhance drug discovery, clinical development, and regulatory submission processes. With over 25 years of experience, the company has established itself as ...
based inCambridge, UNITED KINGDOM
We’re driven by the shared purpose of breaking new ground in the discovery of new treatments for rare diseases. Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to ...
Our Rare Treatment Accelerator helps academic, patient, and industry groups advance their rare disease drug redevelopment projects. By combining our team, expertise and financial resources with your research and insights, we can get treatments to ...
based inSan Diego, CALIFORNIA (USA)
Everyone at AnaBios shares a passion and commitment to make a difference in the development of promising new therapies and cures for patients by reducing the time and expense needed to bring these medicines to patients. We do this by generating ...
Primary human cryopreserved hepatocytes are ideal for many scientific applications, including toxicity, metabolism, disease modeling, genomics, enzyme-mediated mechanisms, uptake, intrinsic clearance and more. When ...
based inNewark, DELAWARE (USA)
ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across ...
based inSchlieren, SWITZERLAND
InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Our robust and highly physiologically relevant suite of ...
Test efficacy of anti-NASH drugs in an advanced 3D human liver disease model. The InSphero 3D InSight™ Human Liver NASH Model consists of an advanced microtissue co-culture of healthy primary ...
based inNewcastle Upon Tyne, UNITED KINGDOM
Newcells offers expert disease modelling services using best in class in vitro platforms and supports drug development by providing robust data for regulatory submissions and the critical decision-making process. Newcells mission is to de-risk the ...
In vitro retinal disease modelling for retinal therapy. Newcells offers a fast and reliable in vitro safety and efficacy service for the evaluation of novel compounds for retinal therapy using complex human retinal ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
15(R)-Lipoxin A4 (15-epi-LXA4) is a STAT-6 activator and a lipid-derived lipoxin-type specialized pro-resolving mediator (SPM) that plays a role in promoting inflammation resolution and regulating immune cell function. 15(R)-Lipoxin A4 can improve ...
based inLeiden, NETHERLANDS
We are a global leader in human 3D disease modeling using our organ-on-a-chip platform, the OrganoPlate. We work with top pharmaceutical and biotech companies to develop novel therapies against unsolved diseases. Our human tissue & disease modeling ...
OrganoReady® Angiogenesis HUVEC comprises 64 HUVEC tubules ready-to-sprout. The product is based on the OrganoPlate® 3-lane 64 with 3 adjacent channels per chip, including one perfused HUVEC tubule. Do you want to perform experiments in ...
based inShirley, NEW YORK (USA)
Creative Bioarray is a leading customer-centered biotechnology company and a pioneer with the latest technology of cell patterning. Creative Bioarray has an experienced expert team and is committed to providing comprehensive services and customized ...
GLP studies are done only for development compounds being prepared for clinical trials. Creative Bioarray has conducted in vivo testing for cardiovascular disease using in vivo models for both side-effect profiling ...
based inBoston, MASSACHUSETTS (USA)
At Emulate, we understand that animal studies and reductionist models are limited because they are not based on integrated human biology. By leveraging 21st century technologies, we are able to overcome these limitations with living human in vitro ...
based inBeijing, CHINA
Founded in 2010 and with a registered capital of 10 million yuan, Beijing Huironghe Technology Co., Ltd. locates at Zhongguancun Science and Technology Park, Tongzhou District, Beijing, specializes in R&D, production, sales and technical services of ...
based inHuangpu District, CHINA
Moon (Guangzhou) Biotech Co., Ltd., with the title of National High-tech Enterprise, is an innovative biotechnology company focusing on the development and commercialization of microbial products and solutions. With a dedication to discover, ...
based inShirley, NEW YORK (USA)
As a scientists-founded and scientists-driven leading biotechnological company, Creative Biogene focuses on developing high quality products and services, as well as proprietary technology to support the research in the field of basic life sciences ...
The mammalian ERCC1 (Excision Repair Cross Complementing) polypeptide is required for nucleotide excision repair (NER) of damaged DNA and is homologous to Saccharomyces cerevisiae RAD10, which functions in repair and mitotic intrachromosomal ...
based inHeidelberg, GERMANY
Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the areas of in silico and precision medicine since 2004. Molecular Health’s solutions make it possible to ...
Reliable predictions to anticipate risks. Interlinked data to find new targets and design novel drugs. Real-world evidence to evaluate success. These capabilities eliminate the uncertainties that limit drug development but are data-intensive and ...
based inTel Aviv, ISRAEL
The volume of human molecular data is growing exponentially, but our analytic capabilities are growing linearly, at best. Humans alone cannot process all this data. What’s needed is a technology capable of digesting, organizing and making sense of ...
The first model to map and compare treatments, patient groups and disease mechanisms. ...
based inBangalore, INDIA
Cellworks’ mission is to serve patients through advances in personalized medicine that significantly improve treatment success. We achieve better outcomes by predicting a successful match between patients and drug therapies – their Therapy Response ...
The Cellworks Platform biosimulates how a patient’s unique cancer will respond to therapies prior to treatment and identifies novel drug combinations for treatment-refractory patients. Therapy biosimulation is the ability to predict the ...
based inLa Jolla, California, CALIFORNIA (USA)
AAA Biotech’s antibodies are highly validated and can be used in multiple applications such as ELISA, FC, ICC, IF, IHC, IP, WB, etc. We have antibodies available for rare species and in multiple conjugated forms, in addition to an extensive ...
based inNaarden, NETHERLANDS
Azafaros has leveraged on decades of discovery by professors Hans Aerts, Hermen Overkleeft, and Stan van Boeckel at Leiden University and the Academic Medical Center in the Netherlands. Expanding on their research and led by highly experienced ...
Azafaros B.V. is pioneering the development of innovative oral small molecule compounds addressing the pathological effects of metabolite accumulation in rare metabolic disorders. Their lead compound, nizubaglustat, leverages unique dual-mode ...